#HepCantWait, but the legacy effect of stigma and discrimination ‘doesn’t just go away’

Since late 2019, COVID-19 has been the global health crisis absorbing much of our attention. Efforts to respond to it, including the redeployment of people and resources, have necessarily had impacts on other public health programs and pandemics. The World Health Organization’s ambitious goal to eliminate hepatitis C by 2030 is one program that has been slowed and, in some places, stopped in its tracks by COVID-19.

READ MORE »

The New South Wales Mandatory Disease Testing Act

The Mandatory Disease Testing Act 2021, recently passed through the New South Wales Parliament,establishes a new scheme under which a person can be ordered to provide a blood sample for the testing of blood-borne viruses if, as a result of their deliberate action, their bodily fluid has come into contact with a health, emergency or public sector worker.

READ MORE »

Life after cure – preliminary findings from the post-cure project

What does life look like for people after they have cleared hepatitis C? Do people whose blood shows no detectable amount of the hepatitis C virus need to inform their doctor or dentist about their previous hepatitis C status? What about prospective employers or insurance providers? Does hepatitis C–related stigma and discrimination remain a challenge for people post-cure? In what ways, and in what settings?

READ MORE »

Hepatitis C cure and ongoing challenges in post-cure lives

Australia is spending billions on the universal rollout of direct-acting antiviral drugs (DAAs) as part of its ambitious goal of achieving virtual elimination of hepatitis C by 2030. These ‘revolutionary’, ‘transformative’ drugs can bring about a sustained virological response – that is, a cure – for hepatitis C in over 90 percent of people treated. They are available on the Pharmaceutical Benefits Scheme for all Australians who are covered by Medicare.

READ MORE »

Hepatitis C from disability to cure – preliminary findings from ‘speculative legal mapping’

As Australia works towards its ambitious target of reducing hepatitis C stigma by 50% by 2022, it is necessary to investigate and understand the issues that continue to affect people who have – and have been treated for – hepatitis C. One significant example of such issues is the set of laws and policies devised in a pre-cure world that have yet to be reformed since the advent of curative treatments. Do people who had hepatitis C need to disclose this to insurers or prospective employers? And could you be refused employment or insurance on such a basis? Does the fact you once had hepatitis C need to be retained in your medical records? There are literally dozens of questions like these to be asked.

READ MORE »

Welcome to GLaD

We are delighted to introduce you to a new research program at the Australian Research Centre in Sex, Health and Society (ARCSHS).

READ MORE »

An interview with GLaD research lead Kate Seear

Australia has long been a leader in critical alcohol and other drug (AOD) scholarship. Much of this work draws on feminist theory, including feminist science studies, to identify and examine ideas about agency and materiality in drug policy and practice. Often, this work also prioritises issues specific to gender, such as how the law conceptualises links between drugs and family violence, or how it understands the relationship between alcohol and sexual assault.

READ MORE »